20.500.12556/RUL-178019 Autoantibodies in COVID-19 convalescent plasma donors Background and Objectives: Although COVID-19 convalescent plasma (CCP) has been successfully used to treat several viral infections, its effectiveness in neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its broader immunological safety remain debated. Since viral infections can trigger autoimmunity, particularly through molecular mimicry and immune dysregulation, there is growing interest in understanding whether CCP contains autoantibodies that could affect recipient safety. Materials and Methods: In this study, we evaluated the presence of 20 different autoantibodies, along with anti-SARS-CoV-2 antibodies, in plasma samples from CCP donors. Samples were collected at three time intervals following COVID-19 symptom onset: 0–60, 60–120 and 120–180 days. Results were compared with those from healthy control plasma donors. Results: Several autoantibodies— anti-Smith (anti-SM), anti-Sjögren syndrome antigen A, 60-kDa isoform (anti-SSA/Ro60), anti-proliferating cell nuclear antigen (anti-PCNA), anti-Ribosomal P and anti-ribonucleoprotein/Smith antigen complex (anti-RNP/SM)—showed modestly elevated levels in CCP samples collected within 0–60 days post symptom onset. In the 60–120-day period, autoantibody levels declined and approached levels observed in the control group. In the 120–180-day period, most autoantibody levels remained comparable to control levels. Our analysis showed no significant correlations between levels of neutralizing SARS-CoV-2 antibodies and autoantibody concentrations nor significant differences in autoantibody profiles between donors with high and low neutralizing antibody (NAb) titres. Conclusion: Our findings suggest that SARS-CoV-2 infection may transiently elevate certain autoantibodies in CCP donors. However, most autoantibody levels decline over time and the overall profiles do not indicate sustained autoreactivity. These results support the immunological safety of CCP, particularly when collected between 60 and 120 days post infection, and highlight the importance of timing in optimizing both efficacy and safety in plasma donation strategies. COVID‐19 convalescent plasma anti‐SARS‐CoV‐2 antibodies autoantibodies transfusion plazma okrevalca po COVID-19 protitelesa proti SARS-CoV-2 avtoprotitelesa transfuzija true false true Angleški jezik Slovenski jezik Članek v reviji 2026-01-16 09:38:24 2026-01-16 09:38:24 2026-01-17 04:38:19 0000-00-00 00:00:00 2026 0 0 Str. 54–63 iss. 1 Vol. 121 2026 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.1 0042-9007 10.1111/vox.70140 258034435 Vox_Sanguinis_-_2025_-_Jazbec_Gradisar_-_Autoantibodies_in_COVID‐19_convalescent_plasma_donors.pdf Vox_Sanguinis_-_2025_-_Jazbec_Gradisar_-_Autoantibodies_in_COVID‐19_convalescent_plasma_donors.pdf 1 E8410CCD0DC8F865303C823874CAF3B6 558760ba8240f16c75fff158301fb3ec718d947be009820a394b8ef662e5c175 d72f5a25-f2b6-11f0-bf92-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=225514 https://onlinelibrary.wiley.com/doi/10.1111/vox.70140 1 aecc0167-f2b6-11f0-bf92-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=225513 Biotehniška fakulteta 0 0 0